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In general this could be achieved by searching new ways for selective active drug accumulation in cancer cells by manipulating 
local drug metabolism or delivery. In this short review, on the basis of the main directions described by McFadyen et al. (Mol 
Cancer Ther 2004; 3(3): 363-371), new data is reported for localization and expression of cytochrome P450 enzymes in hu-
man tumors, development of cytochrome P450-based and gene-directed enzyme activated prodrugs, antisense-based P450 and 
immune-based therapy, cytochrome P450 polymorphism in development of anticancer drugs. New discoveries of molecular bi-
ology of cancer give us hope for more successful development of modern cancer chemotherapy. Biomed Rev 2017; 28: 120-124.
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The cytochrome P450 superfamily of hemoproteins are in-
volved in the oxidative metabolism of a wide range of toxic 
the response of established tumors to anticancer drugs; these 
enzymes can either activate or deactivate many anticancer 
drugs. The outcome, in terms of drug activation (i.e., results 
in cytotoxicity) or deactivation (i.e. no cytotoxicity and po-
tentially resistance), is dependent upon the relative amount 
The 
toxicity of anticancer agents by selective manipulation of the 
expression and activity of different cytochrome P450s in tu-
mor cells (2).
Localization and Expression of Cytochrome P450 Enzymes 
in Human Tumors
A recent comprehensive overview showed expression of 
practically all the cytochrome P450 superfamily in human 
bronchial and peripheral lung tissue with high inter-individu-
al variety of expression in non-small lung cancer cells which 
in turn could explained the different individual susceptibility 
towards the deleterious effects of inhaled chemical toxicants 
and carcinogens (3). A well-known fact is the presence of 
metabolically active CYP1B1 -
 (4). Over 
expression 
also in tumors of the lung, breast, liver, gastrointestinal tract, 
prostate and bladder which turns it into a crucial factor in 
cancerogenesis as well as in an important target for success-
 an early-
stage tumor marker (12). CYP2W1 has also 
(13) and the extent of this expression could serve as an inde-
pendent prognostic factor for overall survival (14). Elevated 
CYP1A1 expression was shown in human bladder cancer 
relative to normal human tissues (15). CYP2J2 was found 
to be overexpressed in adenocarcinoma and breast carcino-
ma as well as in hematopoietic system malignant cells (16). 
121
 in breast carcinoma (3). All recent 
tumour is likely to be an important determinant in predicting 
the outcome of cancer chemotherapy (17).
Anticancer Drugs Metabolized by Cytochrome P450 Enzymes 
Several anticancer agents are metabolized by one or more 
cytochrome P450s with two different outcomes of the cor-
responding metabolites: deactivation or activation (18, 19) 
-
bicin reduction under anaerobic conditions was found.
Development of Cytochrome P450-
Based Activated Prodrugs
different cytochrome P450 isoforms in 
human tumor cells allows the synthesis 
of selectively activated prodrugs (20), 
like:
Anticancer nitric oxide donors aryl 
oximes, N-nitrosamines, N-hydroxyguanidines (21).
Phortress (dihydrochloride salt of 2-(4-amino-3-methyl 
-
lectively) after sequestration only in benzothiazole sen-
sitive (MCF-7 breast) cells and binding to cytosolic aryl 
hydrocarbon receptor (AhR), proceeds with translocation 
of the complex to the cell nucleus where the consistent ac-
to reactive electrophilic species and results in 
formation. Phortress is active against ovarian, breast and 
colorectal cancer (22-24).
 Phortress-like cytotoxic action after 
-
a novel pro-
 potent long-lived 
and cell-permeable cytotoxic metabolite (25).
 active metabolite 
Piceatannol, a tyrosine kinase inhibitor with antileukaemic 
activity (scheme 1) (26, 27).
Pro-drug analogs of duocarmycin were activated by 
Bioreductive Anticancer Drugs
Hypoxic tumors have very poor prognosis and do not re-
spond to existing chemotherapy thus requiring another ther-
apeutic approach  bioreductive drug activation. The prin-
ciple of bioreductive drug activation is that in the reductive 
environment created by hypoxia, endogenous reductases 
will transfer electrons to a nontoxic prodrug to generate a 
Cytochrome P450’s Drugs Deactivation Activation
CYP1A2 no yes
CYP2A6 Ftorafur, Tegafur no yes
CYP2B
Altretamine yes no
Cyclophosphamide, Ifosfamide, Procarbazine, Thiotepa no yes
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reduced cytotoxic metabolite (28). Hence, this provides for 
differential killing of hypoxic tumors versus normal tissues. 
Here are some typical examples:
mitomycin C (19).
aromatic and heterocyclic nitro compounds (RSU1069, 
CB1954, pimonidazole) (29).
aliphatic N-oxides: AQ4N (Novacea) is activated by 
-
tive topoisomerase inhibitor AQ4 (30).
benzotriazine di-N-oxides derivatives (tirapazamine) (31).
Recent experiments showed that combining selective 
downregulation of cytochrome P450 reductase with new-
 to 2-nitroimi-
dazole (code name KEMTUB012-NI2) shows higher ef-
hypoxic tumor cells with limited systemic toxicity (31).
Gene Therapy: Targeting Drug and Enzyme to the Tumor
Confers on tumor cells the genetic capacity to activate a prod-
rug locally, within the tumor, and is designed to increase an-




Localized delivery of P450-expressing cells encapsulated 
in cellulose sulphate.
Use of human macrophages transduced with a hypoxia-
Intratumoral delivery of conditionally replicating oncolytic 
herpes virus encoding P450.
Hypoxia-targeted gene therapy using an adenovirus that 
gene is delivered to the tumor cell using a suitable gene 
therapy vector, providing for localized, intratumoral prod-
rug activation and enhanced tumor cell killing (29).
Cytochrome P450 Enzymes as a Mechanism of Drug 
Resistance
-
cers leads to the development of drug resistance to anticancer 
drugs are docetaxel, doxorubicin, paclitaxel (in treatment of 
ovarian cancer (33)), mitoxantrone and tamoxifen.
Small Molecule Inhibitors of Cytochrome P450s
-
cer drugs is still under experimental stage. Examples: a meth-
ylated derivative of oxyresveratrol (piceatannol); tetramethyl 
-
which in turns inhibited the enzyme. Another contemporary 
-
cer drugs is their simultaneous delivery with some micellar 
-
plasma stability avoiding the reticuloendothelial system ac-
cumulation (34).
Antisense-Based P450 Therapy
Further options for inhibiting the metabolism of anticancer 





stimulate the immune system against tumor cells expressing 
I
Development and Anticancer Therapy
the successful future development of new anticancer drugs 
(35, 36). At the same time no less important for the clinician 
is to have clear cut information on the patient’s cytochrome 
P450 phenotype, lowering in this way the inter-patient vari-
ability, minimizing side-effects and maximizing therapeutic 
tissue microarrays and protein chips should facilitate the 
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